BRU · UCB.BR
UCB S.A.
€280.00+€9.50 (+3.51%)
UCB S.A.’s quoted price sits in the upper half of its reported 52-week range, 3.28% below the high.
Loading market information…
BRU · IBAB.BR · EUR
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 04:35 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Ion Beam Applications S.A.’s quoted price sits in the upper half of its reported 52-week range, 7.32% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Ion Beam Applications S.A.’s forward annual dividend is €0.25 per share, paid annual. The forward yield is 1.52% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Ion Beam Applications S.A.’s next earnings report is currently expected on Mar 25, 2027, with estimated earnings per share of €0.53. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Ion Beam Applications S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Ion Beam Applications S.A. (IBA) specializes in the creation, production, and maintenance of advanced medical equipment and software systems designed to combat cancer, operating across Belgium, the United States, and numerous other countries. Its operations are structured into two key divisions: Proton Therapy and Other Accelerators, and Dosimetry. The Proton Therapy and Other Accelerators segment is dedicated to the engineering, manufacturing, and upkeep of both clinical and industrial particle accelerators, including cutting-edge proton therapy apparatus. This division also furnishes comprehensive, ready-to-use systems for treating cancer with proton beams, a range of cyclotrons crucial for generating radioisotopes for PET and SPECT imaging, as well as industrial accelerators employed in sterilization and ionization processes. The Dosimetry segment offers instruments and expertise aimed at improving the precision and reducing errors in radiation therapy, medical imaging quality assurance, and calibration. IBA maintains a crucial research and development alliance with the Belgian nuclear research center, SCK CEN, to facilitate the development of Actinium-225 (225Ac), an innovative radioisotope with potential in cancer therapy, and collaborates with the University of Pennsylvania on pioneering research into ConformalFLASH technology. Established in 1986, the company's headquarters are located in Louvain-la-Neuve, Belgium.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:05 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| €259.30M+3.72% vs estimate |
| Q4 2023 | Mar 21, 2024 | -€0.94 | €210.69M-15.72% vs estimate |
|---|
| Q2 2023 | Aug 31, 2023 | €0.27+58.82% vs estimate | €169.20M-47.16% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€280.00+€9.50 (+3.51%)
UCB S.A.’s quoted price sits in the upper half of its reported 52-week range, 3.28% below the high.
€227.60+€6.80 (+3.08%)
Financière de Tubize S.A.’s quoted price sits in the upper half of its reported 52-week range, 9.14% below the high.
€28.90+€0.34 (+1.19%)
Lakefront Biotherapeutics’s quoted price sits in the upper half of its reported 52-week range, 5.92% below the high.
€3.86+€0.21 (+5.75%)
Hyloris Pharmaceuticals S.A.’s quoted price sits in the lower half of its reported 52-week range, 54.05% below the high.
€2.23-€0.03 (-1.11%)
Onward Medical N.V.’s quoted price sits in the lower half of its reported 52-week range, 53.44% below the high.
€0.61€0.00 (0.0%)
Sequana Medical N.V.’s quoted price sits in the lower half of its reported 52-week range, 62.24% below the high.
€3.60-€0.36 (-9.09%)
European Medical Solutions’s quoted price sits in the lower half of its reported 52-week range, 34.55% below the high.
€0.21€0.00 (0.0%)
Celyad Oncology S.A.’s quoted price sits in the lower half of its reported 52-week range, 67.69% below the high.
